Rock Creek Pharmaceuticals, Inc., a pharmaceutical development company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its lead compound is Anatabine citrate, a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs available, such as biologics, steroids, and non-steroidal anti-inflammatories. The company was formerly known as Star Scientific, Inc. and changed its name to Rock Creek Pharmaceuticals, Inc. in June 2014. Rock Creek Pharmaceuticals, Inc. is headquartered in Sarasota, Florida. On September 27, 2016, Rock Creek Pharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Phone844-727-0727
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees5
Next Earnings DateN/A
OptionableNot Optionable
Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Frequently Asked Questions
What is Rock Creek Pharmaceuticals' stock symbol?
Rock Creek Pharmaceuticals trades on the OTCMKTS under the ticker symbol "RCPIQ."
Has Rock Creek Pharmaceuticals been receiving favorable news coverage?
Media headlines about RCPIQ stock have trended very negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Rock Creek Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Rock Creek Pharmaceuticals.
Who are some of Rock Creek Pharmaceuticals' key competitors?
Some companies that are related to Rock Creek Pharmaceuticals include STADA Arzneimittel (STDAF), Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), Tilray (TLRY), USANA Health Sciences (USNA), Canopy Rivers (RIV), Sundial Growers (SNDL), Foamix Pharmaceuticals (FOMX), Chromadex (CDXC), True Drinks (TRUU), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX) and Cyanotech (CYAN).
What other stocks do shareholders of Rock Creek Pharmaceuticals own?
Who are Rock Creek Pharmaceuticals' key executives?
Rock Creek Pharmaceuticals' management team includes the folowing people:
- Dr. Michael John Mullan MBBS (M.D., ), Ph.D., Chairman, Chief Exec. Officer and Pres (Age 62)
- Dr. Curtis Wright IV, Sr. VP and Medical & Clinical Director (Age 70)
How do I buy shares of Rock Creek Pharmaceuticals?
Shares of RCPIQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Rock Creek Pharmaceuticals' stock price today?
One share of RCPIQ stock can currently be purchased for approximately $0.00.
What is Rock Creek Pharmaceuticals' official website?
How can I contact Rock Creek Pharmaceuticals?
Rock Creek Pharmaceuticals' mailing address is 2040 WHITFIELD AVE. SUITE 300, SARASOTA FL, 34243. The company can be reached via phone at 844-727-0727 or via email at [email protected]
MarketBeat Community Rating for Rock Creek Pharmaceuticals (OTCMKTS RCPIQ)
MarketBeat's community ratings are surveys of what our community members think about Rock Creek Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCPIQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCPIQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
